Coherus Oncology (CHRS) FCF Margin Growth (5y) (2019 - 2026)
Powered by 
Analysis
Coherus Oncology (CHRS) FCF Margin Growth (5y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -43,330.00 |
| Mar 31, 2026 | -47,171.00 |
| Dec 31, 2025 | -24,950.00 |
| Sep 30, 2025 | -44,032.00 |
| Jun 30, 2025 | 421,688.00 |
| Mar 31, 2025 | -41,203.00 |
| Dec 31, 2024 | 35,596.00 |
| Sep 30, 2024 | -107,309.00 |
| Jun 30, 2024 | 95,369.00 |
| Mar 31, 2024 | 626,615.00 |
| Jun 30, 2022 | 395,357.00 |
| Mar 31, 2022 | 4.65 Mn |
| Dec 31, 2021 | 1.06 Mn |
| Sep 30, 2021 | 5,465.00 |
| Jun 30, 2021 | 19,614.00 |
| Mar 31, 2021 | 63,635.00 |
| Dec 31, 2020 | -1,129.00 |
| Sep 30, 2020 | 90,567.00 |
| Jun 30, 2020 | 36,081.00 |
| Mar 31, 2020 | 60,172.00 |